Source is CardioExchange News, unless otherwise noted.<\/p>\n
FDA Releases Briefing Documents for Avandia Panel<\/a>, 09 Jul 2010<\/p>\n More Evidence Goes Against Avandia<\/a>, 28 Jun 2010<\/p>\n FDA Panels to Review Rosiglitazone and Dabigatran<\/a>, 10 Jun 2010<\/p>\n CANOE Paddles Into the Avandia Storm<\/a>, 03 Jun 2010<\/p>\n European Heart Journal<\/em> Editors Defend Nissen Editorial<\/a>, 03 May 2010<\/p>\n Industry Affiliation and Position on the Rosiglitazone Controversy<\/a>, 20 Apr 2010, Journal Watch<\/em>, Paul S. Mueller, MD, MPH, FACP<\/p>\n Will the FDA Halt Avandia Safety Study?<\/a>, 19 Apr 2010<\/p>\n Rosiglitazone: When Evidence Is Inconclusive Even After FDA Approval<\/a>, 03 Mar 2010, BLOG: The Expert Is In\u00a0, Sanjay Kaul, MD<\/p>\n More Data on Fracture Risk with Thiazolidinediones<\/a>, 02 Mar 2010, Journal Watch<\/em>, Allan S. Brett, MD<\/p>\n Krumholz on Avandia<\/a>, \u00a025 Feb 2010<\/p>\n Avandia Roundup: AHA & ACC Publish Science Advisory on TZDs; GlaxoSmithKline White Paper<\/a>, 24 Feb 2010<\/p>\n Avandia Remains in the News<\/a>, 23 Feb 2010<\/p>\n Senators and FDA Officials Attack Avandia<\/a>, 20 Feb 2010<\/p>\n